

### **CVD Emergencies in COVID19:**

1. Temporary Emergency Guidance to US Stroke Centers During the COVID-19 Pandemic. *Stroke*. 2020.
2. Chinese Society of Cardiology of Chinese Medical A, Editorial Board of Chinese Journal of Cardiovascular D. Expert consensus on principal of clinical management of patients with severe emergent cardiovascular diseases during the epidemic period of COVID-19. *Zhonghua xin xue guan bing za zhi*. 2020;48(3):189-94.
3. Han Y, Zeng H, Jiang H, Yang Y, Yuan Z, Cheng X, et al. CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic. *Circulation*. 2020.
4. Ierardi AM, Wood BJ, Gaudino C, Angileri SA, Jones EC, Hausegger K, et al. How to Handle a COVID-19 Patient in the Angiographic Suite. *CardioVascular and Interventional Radiology*. 2020.
5. Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, et al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. *Resuscitation*. 2020;151:18-23.
6. Szerlip M, Anwaruddin S, Aronow HD, Cohen MG, Daniels MJ, Dehghani P, et al. Considerations for cardiac catheterization laboratory procedures during the COVID-19 pandemic perspectives from the Society for Cardiovascular Angiography and Interventions Emerging Leader Mentorship (SCAI ELM) Members and Graduates. *Catheter Cardiovasc Interv*. 2020.
7. Tarantini G, Fraccaro C, Chieffo A, Marchese A, Tarantino FF, Rigattieri S, et al. Italian Society of Interventional Cardiology (GISE) Position Paper for Cath lab-specific Preparedness Recommendations for Healthcare providers in case of suspected, probable or confirmed cases of COVID-19. *Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions*. 2020.
8. Thiele H. Cardiovascular emergencies in the COVID-19 pandemic. *Herz*. 2020.

### **CVD Risk Factors /Complications/ Education:**

1. Aghagoli G, Gallo Marin B, Soliman LB, Sellke FW. Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review. *Journal of cardiac surgery*. 2020.
2. Aktöz M, Altay H, Aslanger E, Atalar E, Aytekin V, Baykan AO, et al. [Consensus Report from Turkish Society of Cardiology: COVID-19 and Cardiovascular Diseases. What cardiologists should know. (25th March 2020)]. *Turk Kardiyol Dern Ars*. 2020;48(Suppl 1):1-48.
3. Bansal M. Cardiovascular disease and COVID-19. *Diabetes & metabolic syndrome*. 2020;14(3):247-50.
4. Biondi-Zoccai G, Landoni G, Carnevale R, Cavarretta E, Sciarretta S, Frati G. SARS-CoV-2 and COVID-19: facing the pandemic together as citizens and cardiovascular practitioners. *Minerva Cardioangiol*. 2020.
5. Carter P, Anderson M, Mossialos E. Health system, public health, and economic implications of managing COVID-19 from a cardiovascular perspective. *Eur Heart J*. 2020.
6. Chen C, Chen C, Yan JT, Zhou N, Zhao JP, Wang DW. [Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19]. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2020;48(0):E008.
7. Choi AD, Abbara S, Branch KR, Feuchtner GM, Ghoshhajra B, Nieman K, et al. Society of Cardiovascular Computed Tomography guidance for use of cardiac computed tomography

amidst the COVID-19 pandemic Endorsed by the American College of Cardiology. *Journal of cardiovascular computed tomography*. 2020.

8. Chow N, Fleming-Dutra K, Gierke R, Hall A, Hughes M, Pilishvili T, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-March 28, 2020. *Morbidity and Mortality Weekly Report*. 2020;69(13):382-6.
9. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. *Circulation*. 2020.
10. Climie RE, Marques FZ. Impact, Strategies and Opportunities for Early and Mid-Career Cardiovascular Researchers During the COVID-19 Pandemic. *Circulation*. 2020.
11. DeFilippis EM, Stefanescu Schmidt AC, Reza N. Adapting the Educational Environment for Cardiovascular Fellows-in-Training During the COVID-19 Pandemic. *Journal of the American College of Cardiology*. 2020.
12. Deng Q, Hu B, Zhang Y, Wang H, Zhou X, Hu W, et al. Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China. *International Journal of Cardiology*. 2020.
13. Dixon DL, Van Tassell BW, Vecchié A, Bonaventura A, Talasaz A, Kakavand H, et al. Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19). *Journal of cardiovascular pharmacology*. 2020.
14. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. *Journal of the American College of Cardiology*. 2020.
15. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study. *The European respiratory journal*. 2020.
16. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study. *American journal of respiratory and critical care medicine*. 2020.
17. Edelson DP, Sasson C, Chan PS, Atkins DL, Aziz K, Becker LB, et al. Interim Guidance for Basic and Advanced Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19: From the Emergency Cardiovascular Care Committee and Get With the Guidelines((R))-Resuscitation Adult and Pediatric Task Forces of the American Heart Association in Collaboration with the American Academy of Pediatrics, American Association for Respiratory Care, American College of Emergency Physicians, The Society of Critical Care Anesthesiologists, and American Society of Anesthesiologists: Supporting Organizations: American Association of Critical Care Nurses and National EMS Physicians. *Circulation*. 2020.
18. Emanuelli C, Badimon L, Martelli F, Potočnjak I, Carpusca I, Robinson EL, et al. Call to action for the cardiovascular side of COVID-19. *European heart journal*. 2020.
19. Ferrari R, Di Pasquale G, Rapezzi C. Commentary: What is the relationship between Covid-19 and cardiovascular disease? *Int J Cardiol*. 2020.
20. Foo R, Wang Y, Zimmermann WH, Backs J, Wang DW. Cardiovascular molecular mechanisms of disease with COVID-19. *J Mol Cell Cardiol*. 2020.
21. Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin KJ, Horn E, et al. The Variety of Cardiovascular Presentations of COVID-19. *Circulation*. 2020.

22. Funck-Brentano C, Salem JE, Nguyen LS, Drici MD, Roden DM. Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes. *Arch Cardiovasc Dis*. 2020.
23. Ganatra S, Hammond SP, Nohria A. The Novel Coronavirus Disease (COVID-19) Threat for Patients with Cardiovascular Disease and Cancer. *JACC CardioOncology*. 2020.
24. Gardner W, States D, Bagley N. The Coronavirus and the Risks to the Elderly in Long-Term Care. *Journal of Aging and Social Policy*. 2020.
25. Gonzalez-Jaramillo N, Low N, Franco OH. The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments. *European journal of epidemiology*. 2020.
26. Gori T, Lelieveld J, Munzel T. Perspective: cardiovascular disease and the Covid-19 pandemic. *Basic Res Cardiol*. 2020;115(3):4.
27. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*. 2020.
28. Han H, Xie L, Liu R, Yang J, Liu F, Wu K, et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. *Journal of Medical Virology*. 2020.
29. He XW, Lai JS, Cheng J, Wang MW, Liu YJ, Xiao ZC, et al. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients. *Zhonghua xin xue guan bing za zhi*. 2020;48:E011.
30. Hendren NS, Drazner MH, Bozkurt B, Cooper LT, Jr. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. *Circulation*. 2020.
31. Hulot JS. COVID-19 in patients with cardiovascular diseases. *Arch Cardiovasc Dis*. 2020;113(4):225-6.
32. Kapoor A, Pandurangi U, Arora V, Gupta A, Jaswal A, Nabar A, et al. Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society. *Indian Pacing Electrophysiol J*. 2020.
33. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thrombosis Research*. 2020.
34. Klum M, Urban M, Tigges T, Pielmus AG, Feldheiser A, Schmitt T, et al. Wearable cardiorespiratory monitoring employing a multimodal digital patch stethoscope: Estimation of ecg, pep, lvetand respiration using a 55 mm single-lead ecg and phonocardiogram. *Sensors (Switzerland)*. 2020;20(7).
35. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. *J Cardiovasc Electrophysiol*. 2020.
36. Ky B, Mann DL. COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities. *JACC Basic to translational science*. 2020.
37. Li B, Yang J, Zhao FM, Zhi LL, Wang XQ, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clin Res Cardiol*. 2020;8.
38. Linschoten, Asselbergs FW. CAPACITY-COVID: a European registry to determine the role of cardiovascular disease in the COVID-19 pandemic. *Eur Heart J*. 2020.

39. Lippi G, Henry BM, Sanchis-Gomar F. Physical inactivity and cardiovascular disease at the time of coronavirus disease 2019 (COVID-19). *European journal of preventive cardiology*. 2020;2047487320916823.
40. Liu PP, Blet A, Smyth D, Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. *Circulation*. 2020.
41. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thrombosis Research*. 2020;191:9-14.
42. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. *The American journal of emergency medicine*. 2020.
43. Lupia T, Scabini S, Mornese Pinna S, Di Perri G, De Rosa FG, Corcione S. 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. *Journal of Global Antimicrobial Resistance*. 2020;21:22-7.
44. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. *JAMA Cardiology*. 2020.
45. Mohammadzadeh A. Effectiveness of electronic health care and drug monitoring program to prevent COVID-19 and adherence to therapeutic regimen in patients with ischemic heart disease - A pilot study. *Journal of Military Medicine*. 2020;22(2):139-46.
46. Mungmungpantipantip R, Wiwanitkit V. COVID-19 and cardiovascular disorder. *Minerva Cardioangiol*. 2020.
47. Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. *Zhonghua xin xue guan bing za zhi*. 2020;48:E004.
48. Piva S, Filippini M, Turla F, Cattaneo S, Margola A, De Fulviis S, et al. Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. *Journal of Critical Care*. 2020;58:29-33.
49. Professional Committee for Chronic Disease Management AoCHP. Expert Advice on Hypertension Management in Counties in the Context of SARS-CoV-2 Infection. *Chinese General Practice*. 2020;23(7):770-3.
50. Rauch B. Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemic. *European journal of preventive cardiology*. 2020;2047487320920754.
51. Robert Denniss A, Chow CK, Kritharides L. Cardiovascular and Logistic Issues Associated With COVID-19 Pandemic. *Heart, lung & circulation*. 2020.
52. Shah PB, Welt FGP, Mahmud E, Phillips A, Kleiman NS, Young MN, et al. Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement. *JACC Cardiovascular interventions*. 2020.
53. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. *JAMA Cardiology*. 2020.
54. South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. *American journal of physiology Heart and circulatory physiology*. 2020;318(5):H1084-h90.

55. Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. *Int J Cardiol.* 2020.
56. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. *American journal of hematology.* 2020.
57. Vervoort D, Ma X, Luc JGY, Zieroth S. Rapid Scholarly Dissemination and Cardiovascular Community Engagement to Combat the Infodemic of the COVID-19 Pandemic. *The Canadian journal of cardiology.* 2020.
58. Vivas D, Roldan V, Esteve-Pastor MA, Roldan I, Tello-Montoliu A, Ruiz-Nodar JM, et al. [Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology]. *Revista espanola de cardiologia.* 2020.
59. Vlachakis PK, Tentolouris A, Tousoulis D, Tentolouris N. Current data on the cardiovascular effects of the COVID-19. *Hellenic journal of cardiology: HJC = Hellenike kardiologike epitheorese.* 2020.
60. Vuorio A, Watts GF, Kovanen PT. Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk. *J Intern Med.* 2020.
61. Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series. *Journal of thrombosis and haemostasis: JTH.* 2020.
62. Yang C, Jin Z. An Acute Respiratory Infection Runs Into the Most Common Noncommunicable Epidemic-COVID-19 and Cardiovascular Diseases. *JAMA Cardiol.* 2020.
63. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nature reviews Cardiology.* 2020;17(5):259-60.
64. Zhu H, Rhee JW, Cheng P, Waliyan S, Chang A, Witteles RM, et al. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response. *Curr Cardiol Rep.* 2020;22(5):32.
65. Zhu H, Rhee JW, Cheng P, Waliyan S, Chang A, Witteles RM, et al. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response. *Current Cardiology Reports.* 2020;22(5).
66. Zhu ZW, Tang JJ, Chai XP, Fang ZF, Liu QM, Hu XQ, et al. Comparison of heart failure and 2019 novel coronavirus pneumonia in chest CT features and clinical characteristics. *Zhonghua xin xue guan bing za zhi.* 2020;48:E007.

### **CVD Drugs and COVID19:**

1. Alifano M, Alifano P, Forgez P, Iannelli A. Renin-angiotensin system at the heart of COVID-19 pandemic. *Biochimie.* 2020;174:30-3.
2. Battistoni A, Volpe M. Might renin-angiotensin system blockers play a role in the COVID-19 pandemic? *European heart journal Cardiovascular pharmacotherapy.* 2020.
3. Buckley LF, Cheng JWM, Desai A. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2. *J Cardiovasc Pharmacol.* 2020.
4. Cava C, Bertoli G, Castiglioni I. In silico discovery of candidate drugs against covid-19. *Viruses.* 2020;12(4).

5. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. *Cardiovascular research*. 2020.
6. Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. *Journal of Medical Virology*. 2020.
7. Cure E, Cumhur Cure M. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(4):349-50.
8. Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. *Hypertension (Dallas, Tex: 1979)*. 2020.
9. Deftereos SG, Siasos G, Giannopoulos G, Vrachatis DA, Angelidis C, Giotaki SG, et al. The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design. *Hellenic Journal of Cardiology*. 2020.
10. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? *Journal of hypertension*. 2020;38(5):781-2.
11. Goldstein MR, Poland GA, Graeber CW. Are certain drugs associated with enhanced mortality in COVID-19? *QJM: monthly journal of the Association of Physicians*. 2020.
12. Gracia-Ramos AE. Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection? *Archives of Medical Research*. 2020.
13. Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *J Am Heart Assoc*. 2020;9(7):e016219.
14. Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *J Am Heart Assoc*. 2020;9(7):e016219.
15. Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System—a Call for Epidemiologic Investigations. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. 2020.
16. Huang Z, Jiang Y, Chen J, Zhou Y. Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19. *Cardiology journal*. 2020.
17. Iaccarino G, Borghi C, Cicero AFG, Ferri C, Minuz P, Muiesan ML, et al. Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. *High Blood Press Cardiovasc Prevent*.4.
18. Kow CS, Zaidi STR, Hasan SS. Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19. *Am J Cardiovasc Drugs*.5.
19. Li G, Hu R, Zhang X. Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension. *Hypertens Res*. 2020.
20. Li G, Hu R, Zhang XJ. Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension. *Hypertens Res*.3.

21. Marin GH. Facts and reflections on COVID-19 and anti-hypertensives drugs. Drug discoveries & therapeutics. 2020.
22. Meng J, Xiao GH, Zhang JJ, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. *Emerg Microbes Infect.* 2020;9(1):757-60.
23. Phadke M, Saunik S. COVID-19 treatment by repurposing drugs until the vaccine is in sight. *Drug Dev Res.*3.
24. Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. *Current Cardiology Reports.* 2020;22(5).
25. Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. *eLife.* 2020;9.
26. Sommerstein R, Kochen MM, Messerli FH, Gräni C. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? *Journal of the American Heart Association.* 2020;9(7):e016509.
27. Touyz RM, Li H, Delles C. ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19. *Clin Sci (Lond).* 2020;134(7):747-50.
28. Wang Z, Xu X. scRNA-seq Profiling of Human Testes Reveals the Presence of the ACE2 Receptor, A Target for SARS-CoV-2 Infection in Spermatogonia, Leydig and Sertoli Cells. *Cells.* 2020;9(4).

### **CVD Surgery and Anesthesia in COVID19:**

1. Aminnejad R, Shafiee H. Is Regional Anesthesia Enough Safe in Suspected or Confirmed COVID-19 Patients? *ACS chemical neuroscience.* 2020.
2. Bajwa S, Sarna R, Bawa C, Mehdiratta L. Peri-operative and critical care concerns in coronavirus pandemic. *Indian J Anaesth.* 2020;64(4):267-74.
3. Barros L, Rivetti LA, Furlanetto BH, Teixeira EM, Welikow A. COVID-19: GENERAL GUIDELINES FOR CARDIOVASCULAR SURGEONS (standard guidelines - subject to change). *Braz J Cardiovasc Surg.* 2020;35(2):I-III.
4. Bauer M, Bernstein K, Dinges E, Delgado C, El-Sharawi N, Sultan P, et al. Obstetric Anesthesia During the COVID-19 Pandemic. *Anesthesia and analgesia.* 2020.
5. Chen X, Liu Y, Gong Y, Guo X, Zuo M, Li J, et al. Perioperative Management of Patients Infected with the Novel Coronavirus: Recommendation from the Joint Task Force of the Chinese Society of Anesthesiology and the Chinese Association of Anesthesiologists. *Anesthesiology.* 2020.
6. Coimbra R, Edwards S, Kurihara H, Bass GA, Balogh ZJ, Tilsed J, et al. European Society of Trauma and Emergency Surgery (ESTES) recommendations for trauma and emergency surgery preparation during times of COVID-19 infection. *European Journal of Trauma and Emergency Surgery.* 2020.
7. Cook TM, El-Boghdadly K, McGuire B, McNarry AF, Patel A, Higgs A. Consensus guidelines for managing the airway in patients with COVID-19: Guidelines from the Difficult Airway Society, the Association of Anaesthetists the Intensive Care Society, the Faculty of Intensive Care Medicine and the Royal College of Anaesthetists. *Anaesthesia.* 2020.
8. Dexter F, Parra MC, Brown JR, Loftus RW. Perioperative COVID-19 Defense: An Evidence-Based Approach for Optimization of Infection Control and Operating Room Management. *Anesthesia and analgesia.* 2020.

9. He Y, Wei J, Bian J, Guo K, Lu J, Mei W, et al. Chinese Society of Anesthesiology Expert Consensus on Anesthetic Management of Cardiac Surgical Patients With Suspected or Confirmed Coronavirus Disease 2019. *Journal of Cardiothoracic and Vascular Anesthesia*. 2020
10. Hiramatsu M, Nishio N, Ozaki M, Shindo Y, Suzuki K, Yamamoto T, et al. Anesthetic and surgical management of tracheostomy in a patient with COVID-19. *Auris Nasus Larynx*. 2020.
11. Li W, Huang J, Guo X, Zhao J, Mandell MS. Anesthesia Management and Perioperative Infection Control in Patients With the Novel Coronavirus. *Journal of Cardiothoracic and Vascular Anesthesia*. 2020.
12. Lie SA, Wong SW, Wong LT, Wong TGL, Chong SY. Practical considerations for performing regional anesthesia: lessons learned from the COVID-19 pandemic. *Can J Anesth*.8.
13. Mavioglu HL, Unal EU. Cardiovascular surgery in the COVID-19 pandemic. *Journal of cardiac surgery*. 2020.
14. Odor PM, Neun M, Bampoe S, Clark S, Heaton D, Hoogenboom EM, et al. Anaesthesia and COVID-19: infection control. *British Journal of Anaesthesia*. 2020.
15. Sharma D, Rasmussen M, Han R, Whalin M, Davis M, Kofke WA, et al. Anesthetic Management of Endovascular Treatment of Acute Ischemic Stroke during COVID-19 Pandemic: Consensus Statement from Society for Neuroscience in Anesthesiology & Critical Care (SNACC). *Journal of Neurosurgical Anesthesiology*. 2020.
16. Thomas-Rüddel D, Winning J, Dickmann P, Quart D, Kortgen A, Janssens U, et al. Coronavirus disease 2019 (COVID-19): update for anesthesiologists and intensivists March 2020. *Anaesthesist*. 2020;69(4):225-35.
17. Trujillo A. Response to Wen and Li. Anesthesia Procedure of Emergency Operation for Patients with Suspected or Confirmed COVID-19 (DOI: 10.1089/sur.2020.040). *Surg Infect*.1.
18. Wen XJ, Li YQ. Anesthesia Procedure of Emergency Operation for Patients with Suspected or Confirmed COVID-19. *Surg Infect*. 2020;21(3):299-.
19. Wiesmann T, Volk T, Steinfeldt T, Kubulus C, Doffert J, Wulf H, et al. Regional anesthesia in the COVID-19 pandemic situation - ad hoc recommendation by a panel of experts. *Anesthesiol Intensivmed*. 2020;61:S137-S41.
20. Zhang HF, Bo LL, Lin Y, Li FX, Sun SJ, Lin HB, et al. Response of Chinese Anesthesiologists to the COVID-19 Outbreak. *Anesthesiology*. 2020.
21. Zhao S, Ling K, Yan H, Zhong L, Peng X, Yao S, et al. Anesthetic Management of Patients with COVID 19 Infections during Emergency Procedures. *Journal of Cardiothoracic and Vascular Anesthesia*. 2020;34(5):1125-31.
22. Zhong Q, Liu YY, Luo Q, Zou YF, Jiang HX, Li H, et al. Spinal anaesthesia for patients with coronavirus disease 2019 and possible transmission rates in anaesthetists: retrospective, single-centre, observational cohort study. *British Journal of Anaesthesia*. 2020.

### **Stroke and COVID19:**

1. Baracchini C, Pieroni A, Viaro F, Cianci V, Cattelan AM, Tiberio I, et al. Acute stroke management pathway during Coronavirus-19 pandemic. *Neurological Sciences*. 2020.
2. Fraser JF, Arthur AS, Chen M, Levitt M, Mocco J, Albuquerque FC, et al. Society of NeuroInterventional Surgery recommendations for the care of emergent neurointerventional patients in the setting of covid-19. *Journal of NeuroInterventional Surgery*. 2020.

3. Jin H, Hong C, Chen S, Zhou Y, Wang Y, Mao L, et al. Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. *Stroke and Vascular Neurology*. 2020.
4. Khosravani H, Rajendram P, Notario L, Chapman MG, Menon BK. Protected Code Stroke: Hyperacute Stroke Management During the Coronavirus Disease 2019 (COVID-19) Pandemic. *Stroke*. 2020.
5. Kim HJ, Ko JS, Kim TY, Sci Comm Korean Soc A. Recommendations for anesthesia in patients suspected of COVID-19 Coronavirus infection. *Korean J Anesthesiol*. 2020;73(2):89-91.
6. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurology*. 2020.
7. Paybast S, Emami A, Koosha M, Baghalha F. Novel Coronavirus Disease (COVID-19) and Central Nervous System Complications: What Neurologist Need to Know. *Acta neurologica Taiwanica*. 2020;29(1):24-31.
8. Zhao J, Rudd A, Liu R. Challenges and Potential Solutions of Stroke Care During the Coronavirus Disease 2019 (COVID-19) Outbreak. *Stroke*. 2020.

### **Diet During COVID19:**

1. Butler MJ, Barrientos RM. The impact of nutrition on COVID-19 susceptibility and long-term consequences. *Brain, Behavior, and Immunity*. 2020.

### **Psychological Features During COVID19:**

1. Dong MY, Zheng J. Letter to the editor: Headline stress disorder caused by Netnews during the outbreak of COVID-19. *Health Expect*. 2020;23(2):259-60.
2. Losada-Baltar A, Jiménez-Gonzalo L, Gallego-Alberto L, Pedroso-Chaparro MDS, Fernandes-Pires J, Márquez-González M. "We're staying at home". Association of self-perceptions of aging, personal and family resources and loneliness with psychological distress during the lock-down period of COVID-19. *The journals of gerontology Series B, Psychological sciences and social sciences*. 2020.
3. Rajkumar RP. COVID-19 and mental health: A review of the existing literature. *Asian Journal of Psychiatry*. 2020;52.
4. Tian F, Li H, Tian S, Yang J, Shao J, Tian C. Psychological symptoms of ordinary Chinese citizens based on SCL-90 during the level I emergency response to COVID-19. *Psychiatry Research*. 2020;288.
5. Yuan S, Liao ZX, Huang HJ, Jiang BY, Zhang XY, Wang YW, et al. Comparison of the Indicators of Psychological Stress in the Population of Hubei Province and Non-Endemic Provinces in China

During Two Weeks During the Coronavirus Disease 2019 (COVID-19) Outbreak in February 2020. *Med Sci Monitor.* 2020;26:10.

### **Metabolic Syndrome and Related Risk Factors and COVID-19:**

1. Gupta R, Misra A. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infection with reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc). *Diabetes and Metabolic Syndrome: Clinical Research and Reviews.* 2020;14(3):251-4.
2. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Resp Med.* 2020;8(4):E21-E.
3. Gupta R, Misra A. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infection with reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc). *Diabetes and Metabolic Syndrome: Clinical Research and Reviews.* 2020;14(3):251-4.
4. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression: *Diabetes and COVID-19.* *Diabetes and Metabolic Syndrome: Clinical Research and Reviews.* 2020;14(4):395-403.
5. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. *Diabetes Research and Clinical Practice.* 2020;162.
6. Jayawardena R, Sooriyaarachchi P, Chourdakis M, Jeewandara C, Ranasinghe P. Enhancing immunity in viral infections, with special emphasis on COVID-19: A review. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews.* 2020;14(4):367-82.
7. Kassir R. Risk of COVID-19 for patients with obesity. *Obes Rev.* 2.
8. Lakhani A. Which Melbourne Metropolitan Areas Are Vulnerable to COVID-19 Based on Age, Disability, and Access to Health Services? Using Spatial Analysis to Identify Service Gaps and Inform Delivery. *Journal of Pain and Symptom Management.* 2020.
9. Li X, Wang L, Yan S, Yang F, Xiang L, Zhu J, et al. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. *International Journal of Infectious Diseases.* 2020;94:128-32.
10. Lian J, Jin X, Hao S, Cai H, Zhang S, Zheng L, et al. Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America.* 2020.
11. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America.* 2020.
12. Lippi G, Wong J, Henry BM. Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis. *Polish archives of internal medicine.* 2020.
13. Luzi L, Radaelli MG. Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic. *Acta Diabetol.* 6.
14. Mahase E. Covid-19: death rate is 0.66% and increases with age, study estimates. *BMJ-British Medical Journal.* 2020;369:1.

15. Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain MJ. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. *GeroScience*. 2020.
16. Ogen Y. Assessing nitrogen dioxide (NO<sub>2</sub>) levels as a contributing factor to coronavirus (COVID-19) fatality. *Science of the Total Environment*. 2020;726.
17. Rahimi F, Talebi Bezmin Abadi A. Practical Strategies Against the Novel Coronavirus and COVID-19—the Imminent Global Threat. *Archives of Medical Research*. 2020.
18. Russell TW, Hellewell J, Jarvis CI, Zandvoort K, Abbott S, Ratnayake R, et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. *Eurosurveillance*. 2020;25(12).
19. Ryan DH, Ravussin E, Heymsfield S. COVID 19 and the Patient with Obesity - The Editors Speak Out. *Obesity*.1.
20. Saghazadeh A, Rezaei N. Immune-epidemiological parameters of the novel coronavirus—a perspective. *Expert Review of Clinical Immunology*. 2020.
21. Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? *Aging*. 2020.
22. Schiffrin EL, Flack J, Ito S, Muntner P, Webb C. Hypertension and COVID-19. *American journal of hypertension*. 2020.
23. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: Findings of 487 cases outside Wuhan. *Critical Care*. 2020;24(1).
24. Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(4):283-7.
25. Stoian AP, Banerjee Y, Rizvi AA, Rizzo M. Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management. *Metabolic syndrome and related disorders*. 2020.
26. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with covid-19: Evidence from meta-analysis. *Aging*. 2020;12(7):6049-57.
27. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. *Journal of Infection*. 2020.
28. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Internal Medicine*. 2020.
29. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. *International Journal of Infectious Diseases*. 2020;94:91-5.
30. Zhavoronkov A. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections. *Aging*. 2020;12.
31. Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. *European Review for Medical and Pharmacological Sciences*. 2020;24(6):3404-10.

32. Zheng Y, Xu H, Yang M, Zeng Y, Chen H, Liu R, et al. Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu. *Journal of Clinical Virology*. 2020;127.
33. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020;395(10229):1054-62.